|
69
|
233
|
4qw0M |
Ycp beta5-a49t-a50v-double mutant in complex with bortezomib |
|
65
|
240
|
4qwgC |
Ycp beta5-a49v mutant in complex with carfilzomib |
|
60
|
196
|
4qz6N |
Ycp beta5-a49t-a50v double mutant in complex with the epoxyketone inhibitor onx 0914 |
|
61
|
222
|
4qlqL |
Ycp in complex with tripeptidic epoxyketone inhibitor 8 |
|
61
|
195
|
4qz0J |
Ycp beta5-m45v mutant in complex with the epoxyketone inhibitor onx 0914 |
|
68
|
240
|
4qw4C |
Ycp in complex with carfilzomib |
|
60
|
195
|
4qvnJ |
Ycp beta5-m45v mutant in complex with bortezomib |
|
68
|
240
|
4qz3C |
Ycp beta5-a49v mutant in complex with the epoxyketone inhibitor onx 0914 |
|
65
|
242
|
4qwgD |
Ycp beta5-a49v mutant in complex with carfilzomib |
|
59
|
196
|
4r17N |
Ligand-induced aziridine-formation at subunit beta5 of the yeast 20s proteasome |
|
72
|
243
|
4qz5F |
Ycp beta5-a49t-mutant in complex with onx 0914 |
|
66
|
244
|
4qwsB |
Ycp beta5-c63f mutant in complex with carfilzomib |
|
64
|
195
|
4qvwJ |
Ycp beta5-a49s-mutant in complex with bortezomib |
|
70
|
240
|
4qv1C |
Ycp beta5-m45a mutant |
|
61
|
245
|
4r67G |
Human constitutive 20s proteasome in complex with carfilzomib |
|
65
|
241
|
4qz6G |
Ycp beta5-a49t-a50v double mutant in complex with the epoxyketone inhibitor onx 0914 |
|
67
|
250
|
4qwsA |
Ycp beta5-c63f mutant in complex with carfilzomib |
|
68
|
242
|
4qv0D |
Ycp beta5-a49t-a50v-double mutant |
|
61
|
231
|
4qvqE |
Ycp beta5-m45i mutant in complex with bortezomib |
|
63
|
241
|
4qlqG |
Ycp in complex with tripeptidic epoxyketone inhibitor 8 |
|
59
|
222
|
4qzzL |
Ycp in complex with omuralide |
|
58
|
222
|
4qwrL |
Ycp beta5-c52f mutant in complex with carfilzomib |
|
69
|
250
|
4qltA |
Ycp in complex with tripeptidic epoxyketone inhibitor 2 (pr924) |
|
70
|
243
|
4qzzF |
Ycp in complex with omuralide |
|
62
|
195
|
4qxjJ |
Ycp beta5-m45a mutant in complex with the epoxyketone inhibitor onx 0914 |
|
69
|
250
|
4qwfA |
Ycp beta5-m45i mutant in complex with carfilzomib |
|
58
|
222
|
4qv0L |
Ycp beta5-a49t-a50v-double mutant |
|
69
|
250
|
4r02A |
Ycp in complex with bsc4999 (alpha-keto phenylamide) |
|
68
|
240
|
4qwkC |
Ycp beta5-a49t-a50v-double mutant in complex with carfilzomib |
|
67
|
233
|
4qw3M |
Ycp beta5-c63f mutant in complex with bortezomib |
|
61
|
222
|
4qv5L |
Ycp beta5-m45i mutant |
|
57
|
204
|
4qw1I |
Ycp beta5-a50v mutant in complex with bortezomib |
|
61
|
196
|
4qv4N |
Ycp beta5-m45t mutant |
|
60
|
222
|
4qz6L |
Ycp beta5-a49t-a50v double mutant in complex with the epoxyketone inhibitor onx 0914 |
|
66
|
233
|
4qvwM |
Ycp beta5-a49s-mutant in complex with bortezomib |
|
68
|
244
|
4qltB |
Ycp in complex with tripeptidic epoxyketone inhibitor 2 (pr924) |
|
62
|
231
|
4qw6E |
Ycp beta5-m45v mutant in complex with carfilzomib |
|
68
|
250
|
4qvnA |
Ycp beta5-m45v mutant in complex with bortezomib |
|
67
|
240
|
4qz4C |
Ycp beta5-a49s mutant in complex with the epoxyketone inhibitor onx 0914 |
|
65
|
212
|
4qvvK |
Ycp beta5-a49v mutant in complex with bortezomib |
|
61
|
222
|
4qv8L |
Ycp beta5-c52f mutant |
|
60
|
222
|
4qz7L |
Ycp beta5-a50v mutant in complex with the epoxyketone inhibitor onx 0914 |
|
56
|
222
|
4qwsH |
Ycp beta5-c63f mutant in complex with carfilzomib |
|
71
|
244
|
4qv7B |
Ycp beta5-a50v mutant |
|
70
|
242
|
4qlqD |
Ycp in complex with tripeptidic epoxyketone inhibitor 8 |
|
65
|
231
|
4qzxE |
Ycp beta5-c63f mutant in complex with the epoxyketone inhibitor onx 0914 |
|
66
|
228
|
4qxjM |
Ycp beta5-m45a mutant in complex with the epoxyketone inhibitor onx 0914 |
|
71
|
240
|
4qv9C |
Ycp beta5-c63f mutant |
|
61
|
195
|
4qlsJ |
Ycp in complex with tripeptidic epoxyketone inhibitor 11 |
|
66
|
242
|
4qz1D |
Ycp beta5-m45t mutant in complex with the epoxyketone inhibitor onx 0914 |
